Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada.

Knowles SR, Phillips EJ, Dresser L, Matukas L
Clin Infect Dis. 2003 37 (8): 1139-42

PMID: 14523782 · PMCID: PMC7204073 · DOI:10.1086/378304

Although information on efficacy and adverse drug reactions is lacking, ribavirin has been used empirically for the treatment of severe acute respiratory syndrome (SARS). We report common adverse events in 110 patients with suspected or probable SARS who were treated with ribavirin. Sixty-one percent of the patients had evidence of hemolytic anemia, and hypocalcemia and hypomagnesmia were reported in 58% and 46% of patients, respectively.

MeSH Terms (15)

Adolescent Adult Aged Aged, 80 and over Anemia, Hemolytic Antiviral Agents Canada Disease Outbreaks Female Humans Hypocalcemia Male Middle Aged Ribavirin Severe Acute Respiratory Syndrome

Connections (1)

This publication is referenced by other Labnodes entities: